Oncorus is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. Co.'s two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, Co.'s main product candidate, is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A, or CVA21, encapsulated within an lipid nanoparticle. Co. is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus, or SVV. Both CVA21 and SVV have extensive clinical experience and safety profiles when administered IV. We show 11 historical shares outstanding datapoints in our ONCR shares outstanding history coverage, used to compute ONCR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ONCR market cap history over the course of time is important for investors
interested in comparing ONCR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ONCR versus a peer is one thing; comparing
ONCR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ONCR can fluctuate over the course of history.
With this page we aim to empower investors researching ONCR by allowing them to research the ONCR market cap history. |
Free ONCR Email Alerts:
Video: The Importance of Market Cap
